Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 33, 2009, Pages 13754-13758

  Lladó, Victoria ^a   Terés, Silvia ^a   Higuera, Mónica ^a   Álvarez, Rafael ^a   Noguera Salva, Maria Antònia ^a   Halver, John E ^b   Escribá, Pablo V ^a   Busquetsa, Xavier ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anticancer; DNA; Membrane lipid therapy; Neoplasia; Nutrigenetics

Indexed keywords

2 HYDROXYOLEIC ACID; CYCLIN D; DIHYDROFOLATE REDUCTASE; ELAIDIC ACID; OLEIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; DRUG INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; FATTY ACIDS; FOLIC ACID ANTAGONISTS; HUMANS; JURKAT CELLS; LEUCOVORIN; LIPIDS; METHOTREXATE; NEOPLASMS; OLEIC ACIDS; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 69549088660     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907300106     Document Type: Article

References (33)

1. Martínez J, et al. (2005) Membrane structure modulation, protein kinase Cα activation, and anticancer activity of minerval. Mol Pharmacol 67:531-540. (Pubitemid 40216746)
2. Lladó V, et al. (December 24, 2008) Minerval induces apoptosis in jurkat and other cancer cells. J Cell Mol Med, 10.1111/j.1582-4934.2008.00625.x.
3. Martínez J, et al. (2005) The repression of E2F-1 is critical for the activity of Minerval against cancer. J Pharmacol Exp Ther 315:466-474. (Pubitemid 41380543)
4. Escribá PV, Sastre M, Garcia-Sevilla JA (1995) Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures. Proc Natl Acad Sci USA 92:7595-7599.
5. Escribá, PV (2002) Membrane-lipid therapy: A new approach in molecular medicine. Trends Mol Med 12:34-43.
6. Israel M, Modest EJ, Frei E III (1975) N-trifluoroacetyladriamycin-14- valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35:1365-1368.
7. Escribá PV, et al. (1997) Role of lipid polymorphism in G protein-membrane interactions: Nonlamellar-prone phospholipids and peripheral protein binding to membranes. Proc Natl Acad Sci USA 94:11375-11380.
8. Yang Q, et al. (2005) Influence of the membrane lipid structure on signal processing via G protein-coupled receptors. Mol Pharmacol 68:210-217. (Pubitemid 41002960)
9. Escribá PV, Morales P, Smith A (2002) Membrane phospholipid reorganization differentially regulates metallothionein and heme oxygenase by heme-hemopexin DNA. Cell Biol 21:355-364. (Pubitemid 34594548)
10. Michaeli J, et al. (1992) A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis. J Biol Chem 267:23463-23466. (Pubitemid 23088139)
11. Barceló F, et al. (2004) The hypotensive drug 2-hydroxyoleic acid modifies the structural properties of model membranes. Mol Membr Biol 21:261-268. (Pubitemid 39208301)
12. Prades J, Funari SS, Escribá PV, Barceló F (2003) Effects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structure. J Lipid Res 44:1720-1727. (Pubitemid 37203342)
13. Gangjee A, Jain HD (2004) Antifolates: Past, present and future. Curr Med Chem Anticancer Agents 4:405-410.
14. Gangjee A, Jain HD, Kurup S (2007) Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part I. Anticancer Agents Med Chem 7:524-542. (Pubitemid 351836124)
15. Bertino JR (1993) Karnofsky memorial lecture. Ode tomethotrexate. J Clin Oncol 11:5-14.
16. Teres S, et al. (2008) Oleic acid content is responsible for the reduction in blood pressure induced by olive oil. Proc Natl Acad Sci USA 105:1381-13816.
17. Slansky JE, Li Y, Kaelin WG, Farnham PJ (1993) A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 13:1610-1618. (Pubitemid 23068099)
18. Sowers R, et al. (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2:535-541.
19. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677.
20. Strauss G, Osen W, Debatin KM (2002) Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128:255-266. (Pubitemid 34534038)
21. Agathanggelou A, et al. (2003) Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 63:5344-5351. (Pubitemid 37139849)
22. Fimognari C, et al. (2002) Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell Mol Life Sci 59:2004-2012. (Pubitemid 36015873)
23. Yu C, et al. (2003) The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63:1822-1833. (Pubitemid 36460844)
24. Escribá PV, et al. (2008) Membranes: A meeting point for lipids, proteins and therapies. J Cell Mol Med 12:829-875.
25. Jendrossek V, Handrick R (2003) Membrane targeted anticancer drugs: Potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents 3:343-353. (Pubitemid 37045712)
26. Zaremberg V, Gajate C, Cacharro LM, Mollinedo F, McMaster CR (2005) Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J Biol Chem 280:38047-38058. (Pubitemid 41642419)
27. 1α by 2-hydroxymyristate does not interfere with its palmitoylation or membrane association. Evidence that palmitoylation, but not myristoylation, regulates membrane attachment. Biochem J 313:717-720.
28. Young AP, Nagarajan R, Longmore GD (2003) Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway. Oncogene 22:7209-7217. (Pubitemid 37378552)
29. Bucle AE (1959) Methotrexate in treatment of metastasizing chorioncarcinoma: A case report. Br Med J 2:1210-1213.
30. Mayer-Kuckuk P, et al. (2002) Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: Amethod to modulate gene expression. Proc Natl Acad Sci USA 99:3400-3405. (Pubitemid 34252121)
31. Fotoohi AK, Albertioni F (2008) Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 49:410-426.
32. Giovannetti E, et al. (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110-118. (Pubitemid 41002949)
33. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36.